FDA Accepts Revance Resubmission for Frown Line Treatment
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
A new analysis points to aging patients, rising med-spa volume, and next-generation HA and biostimulatory formulas as drivers behind the projected jump to an $8.45B global fillers market.